NCT00001495View on ClinicalTrials.gov

A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

November 30, 1995

Study Completion Date

October 31, 2000

Conditions

Neoplasms

Interventions

DRUG

irinotecan (CPT-11)

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH